Tumor-Associated Mast Cells Drive Immunosuppression and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4-mediated Regulatory T-Cell Recruitment.
- 1Key Laboratory of Myocardial Ischemia, Ministry of Education, The Second Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China.
- 2Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China.
Abstract
This study investigated how tumor-associated mast cells (TAMCs) contribute to immunosuppression and anti-PD-1 resistance in hepatocellular carcinoma (HCC). TAMC infiltration as well as the levels of stem cell factor (SCF) and various chemokines were measured in clinical specimens obtained from 59 HCC patients. The recruitment and maintenance of TAMCs by HCC-conditioned medium were examined, with a focus on the role of SCF in these processes. In addition, the chemotactic effect of CCL17 (secreted by activated TAMCs) on CCR4-expressing regulatory T cells (Tregs) was evaluated. The functional impact of the recruited Tregs was further assessed by examining their capacity to inhibit the proliferation of CD8⁺ T cells and to suppress the secretion of cytotoxic effector molecules. In vivo experiments were also conducted to evaluate the antitumor efficacy of combining anti-PD-1 antibodies with either cromolyn sodium or CCR4 antagonists. Analysis of HCC specimens revealed a marked accumulation of TAMCs, and the extent of TAMC infiltration was found to be positively correlated with both SCF and CCL17 levels. HCC cells were shown to actively recruit TAMCs and promote their proliferation through the secretion of SCF. Upon activation, TAMCs released CCL17, which potently chemotaxed Tregs in a CCR4-dependent manner and subsequently suppressed the antitumor activity of CD8⁺ T cells. In vivo, the combination of anti-PD-1 antibodies with cromolyn sodium or CCR4 antagonists yielded a synergistic antitumor effect, outperforming each agent used as monotherapy. Overall, these findings suggest that TAMCs drive immune suppression and confer resistance to anti-PD-1 therapy in HCC through CCL17/CCR4-mediated Treg recruitment.
Related
- Gαi3 acts as a metabolic checkpoint orchestrating TAMs immunosuppression and lipid metabolism in glucose-deprived hepatocellular carcinoma
- An amyloid-β/APP regulatory layer in human brown adipocyte recruitment identifies repurposable drugs for thermogenic fat expansion
- An immunosuppression imaging gauge prospectively predicts metastatic progression and immunotherapy resistance in breast cancer
- Human Susceptibility to UVB-Induced Immunosuppression Is Associated with UVB-Induced Activation of the DAMP Pathway in the Skin
- Protocol for studying membrane protein dynamics and associated synaptic vesicle recruitment on native membrane sheets
BibTeX
@article{yang2026tumorassociated,
title = {{Tumor-Associated Mast Cells Drive Immunosuppression and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4-mediated Regulatory T-Cell Recruitment.}},
author = {Shuai Yang and Chuang Yang},
journal = {Journal of biochemical and molecular toxicology},
year = {2026},
month = oct,
doi = {10.1002/jbt.71127},
url = {https://europepmc.org/article/MED/42900017},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Tumor-Associated Mast Cells Drive Immunosuppression and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4-mediated Regulatory T-Cell Recruitment.
AU - Shuai Yang
AU - Chuang Yang
PY - 2026
DA - 2026/10/30
JO - Journal of biochemical and molecular toxicology
DO - 10.1002/jbt.71127
UR - https://europepmc.org/article/MED/42900017
AB - This study investigated how tumor-associated mast cells (TAMCs) contribute to immunosuppression and anti-PD-1 resistance in hepatocellular carcinoma (HCC). TAMC infiltration as well as the levels of stem cell factor (SCF) and various chemokines were measured in clinical specimens obtained from 59 HCC patients. The recruitment and maintenance of TAMCs by HCC-conditioned medium were examined, with a focus on the role of SCF in these processes. In addition, the chemotactic effect of CCL17 (secreted by activated TAMCs) on CCR4-expressing regulatory T cells (Tregs) was evaluated. The functional impact of the recruited Tregs was further assessed by examining their capacity to inhibit the proliferation of CD8⁺ T cells and to suppress the secretion of cytotoxic effector molecules. In vivo experiments were also conducted to evaluate the antitumor efficacy of combining anti-PD-1 antibodies with either cromolyn sodium or CCR4 antagonists. Analysis of HCC specimens revealed a marked accumulation of TAMCs, and the extent of TAMC infiltration was found to be positively correlated with both SCF and CCL17 levels. HCC cells were shown to actively recruit TAMCs and promote their proliferation through the secretion of SCF. Upon activation, TAMCs released CCL17, which potently chemotaxed Tregs in a CCR4-dependent manner and subsequently suppressed the antitumor activity of CD8⁺ T cells. In vivo, the combination of anti-PD-1 antibodies with cromolyn sodium or CCR4 antagonists yielded a synergistic antitumor effect, outperforming each agent used as monotherapy. Overall, these findings suggest that TAMCs drive immune suppression and confer resistance to anti-PD-1 therapy in HCC through CCL17/CCR4-mediated Treg recruitment.
SN - 1095-6670
SN - 1099-0461
ER -